09/16/2021 PAC ROOTS CANNABIS CORP. ANNOUNCES FOCUSED STRATEGY
Pac Roots Cannabis Corp. (“Pac Roots” or the “Company”) (CSE: PACR) (OTCQB: PARCF) (FSE:4XM) further to our September 8th 2021 News Release, where Chris Farnworth
INVESTORS
STOCK CHARTS
SHARE CAPITAL
CAPITAL STRUCTURE
As of May 4, 2021
Shares Issued and Outstanding (18.3M in escrow)
87,027,899
Warrants
15,991,674
Stock Options
7,500,000
Fully Diluted
89,252,205
WHY INVEST
GENETICS
Over 350 genetics have been stress
tested and ready for the market.
LATE STAGE
APPLICANT
Our facility and application are making continual progress to become a licensed cannabis producer in Canada.
INDUSTRY
SHATTERING YIELD
With elite genetics and proprietary IP,
PacRoots expects a base yield of 3.1lbs
per light compared to the industry average of 1.5lb per light.
STRAIN SELECTION
Our library of genetics is something
totally unique to the
Canadian Cannabis Market.
Press Releases
09/09/2021 PAC ROOTS CANNABIS CORP. ANNOUNCES NEW CEO & BOARD MEMBER
For Immediate Release
03/19/2021 PAC ROOTS CANNABIS CORP. ANNOUNCES FRANKFURT QUOTATION
VANCOUVER, British Columbia, March 19, 2021 – Pac Roots Cannabis Corp. (“PacRoots” or the “Company”) (CSE: PACR) (OTCQB: PACRF) (FSE: 4XM) is pleased to announce
03/19/2021 PAC ROOTS CANNABIS CORP. ANNOUNCES FRANKFURT QUOTATION
VANCOUVER, British Columbia, March 19, 2021 – Pac Roots Cannabis Corp. (“PacRoots” or the “Company”) (CSE: PACR) (OTCQB: PACRF) (FSE: 4XM) is pleased to announce
01/25/2021 PACROOTS ANNOUNCES PRIVATE PLACEMENT
Vancouver, B.C., January 25, 2021 – Pac Roots Cannabis Corp. (“PacRoots” or the “Company”) (CSE: PACR), announces that it will be conducting a non-brokered private
02/24/2021 PACROOTS CLOSES $1.34M PRIVATE PLACEMENT
Vancouver, B.C., February 24th 2021 Pac Roots Cannabis Corp. (“PacRoots” or the “Company”) (CSE: PACR), announces the closing of its previously announced non-brokered private placement
CORPORATE PRESENTATION
REGULATORY FILINGS
FISCAL YEAR 2021
FISCAL YEAR 2019
For more historical Financial Statements and MD&A and regulatory filings please visit our SEDAR profile.
